Onglyza Stacks Up To Januvia, Bristol/AstraZeneca Say
Executive Summary
Merck has held a monopoly on the dipeptidyl peptidase-4 inhibitor market for type 2 diabetes since launching Januvia (sitagliptin)in 2006 - a franchise that's now approaching blockbuster status - but within the next year it could be sharing scripts with two new rivals
You may also be interested in...
Bristol Readies For Prasugrel’s Impact On Plavix, Files DPP-4 Inhibitor
Despite downplaying any concern, Bristol-Myers Squibb is preparing for a potential challenge to its blockbuster anti-clotting drug Plavix from Lilly/Daiichi Sankyo's Effient (prasugrel)
Diabetes Therapies Need Cardiovascular Safety Data For Approval, Panel Says
Sponsors of new type 2 diabetes therapies should be required to provide clinical data that can exclude an unacceptable cardiovascular risk prior to approval, FDA's Endocrinologic and Metabolic Drugs Advisory Committee concluded at a July 1-2 meeting
Takeda’s Alogliptin Strategy: Treatment Options
With five Phase III wins for type 2 diabetes, company plans to build on Actos’ success.